Citations

Showing 10 of 108104 citations.

miR-219a-5p Regulates Rorβ During Osteoblast Differentiation and in Age-related Bone Loss
Aquino-Martínez, Rubén , Weivoda, Megan , Negley, Brittany A, Onken, Jennifer L, Thicke, Brianne S, Fulcer, McKenzie M, Fraser, Daniel G., Wijnen, André J. van , Rowsey, Jennifer L. , Farr, Joshua N. , Weivoda, Megan M, Monroe, David G. , van Wijnen, Andre J , Fulcer, McKenzie M., Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | October 15, 2018 | Volume: 34 | Issue: 1 | Pages: 135-144

10.1002/jbmr.3586 | PMID 30321475 Get It

ABSTRACT Developing novel approaches to treat skeletal disorders requires an understanding of how critical molecular factors regulate osteoblast differentiation and bone remodeling. We have reported that (1) retinoic acid receptor-related orphan receptor beta (Rorβ) is upregulated in bone samples isolated from aged mice and humans in vivo; (2) Rorβ expression is inhibited during osteoblastic differentiation in vitro; and (3) genetic deletion of Rorβ in mice results in preservation of bone mass during aging. These data establish that Rorβ inhibits osteogenesis and that strict control of Rorβ expression is essential for bone homeostasis. Because microRNAs (miRNAs) are known to play important roles in the regulation of gene expression in bone, we explored whether a predicted subset of nine miRNAs regulates Rorβ expression during both osteoblast differentiation and aging. Mouse osteoblastic cells were differentiated in vitro and assayed for Rorβ and miRNA expression. As Rorβ levels declined with differentiation, the expression of many of these miRNAs, including miR-219a-5p, was increased. We further demonstrated that miR-219a-5p was decreased in bone samples from old (24-month) mice, as compared with young (6-month) mice, concomitant with increased Rorβ expression. Importantly, we also found that miR-219a-5p expression was decreased in aged human bone biopsies compared with young controls, demonstrating that this phenomenon also occurs in aging bone in humans. Inhibition of miR-219a-5p in mouse calvarial osteoblasts led to increased Rorβ expression and decreased alkaline phosphatase expression and activity, whereas a miR-219a-5p mimic decreased Rorβ expression and increased osteogenic activity. Finally, we demonstrated that miR-219a-5p physically interacts with Rorβ mRNA in osteoblasts, defining Rorβ as a true molecular target of miR-219a-5p. Overall, our findings demonstrate that miR-219a-5p is involved in the regulation of Rorβ in both mouse and human bone. © 2018 American Society for Bone and Mineral Research.
PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient
Sinnwell, Jason P. , Yu, Jia , Vedell, Peter T. , Weinshilboum, Richard M. , Wang, Liewei , Goetz, Matthew P. , Thompson, Kevin J. , Ingle, James N. , Suman, Vera, Sinnwell, Jason P , Kalari, Krishna R. , Tang, Xiaojia , Carlson, Erin E. , Weinshilboum, Richard M. , Boughey, Judy C. , Goetz, Matthew P. , Suman, Vera J.

Mayo Clinic

JCO Clinical Cancer Informatics | October 15, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-11

10.1200/cci.18.00012 | PMID 30652605 Get It

Purpose The majority of patients with cancer receive treatments that are minimally informed by omics data. We propose a precision medicine computational framework, PANOPLY (Precision Cancer Genomic Report: Single Sample Inventory), to identify and prioritize drug targets and cancer therapy regimens. Materials and Methods The PANOPLY approach integrates clinical data with germline and somatic features obtained from multiomics platforms and applies machine learning and network analysis approaches in the context of the individual patient and matched controls. The PANOPLY workflow uses the following four steps: selection of matched controls to the patient of interest; identification of patient-specific genomic events; identification of suitable drugs using the driver-gene network and random forest analyses; and provision of an integrated multiomics case report of the patient with prioritization of anticancer drugs. Results The PANOPLY workflow can be executed on a stand-alone virtual machine and is also available for download as an R package. We applied the method to an institutional breast cancer neoadjuvant chemotherapy study that collected clinical and genomic data as well as patient-derived xenografts to investigate the prioritization offered by PANOPLY. In a chemotherapy-resistant patient-derived xenograft model, we found that that the prioritized drug, olaparib, was more effective than placebo in treating the tumor ( P < .05). We also applied PANOPLY to in-house and publicly accessible multiomics tumor data sets with therapeutic response or survival data available. Conclusion PANOPLY shows promise as a means to prioritize drugs on the basis of clinical and multiomics data for an individual patient with cancer. Additional studies are needed to confirm this approach.
Reducing allogeneic blood exposure in low blood volume extracorporeal photopheresis patients through use of a modified blood prime
Su, Leon , Gray, Kristin , Nizzi, Frank, Su, Leon L , Baker, Katie

Mayo Clinic

Journal of Clinical Apheresis | October 15, 2018 | Volume: 33 | Issue: 6 | Pages: 682-684

10.1002/jca.21661 | PMID 30320924 Get It

UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells
Mooneyham, Ashley , Iizuka, Yoshie, Yang, Qing , Coombes, Courtney , McClellan, Mark , Shridhar, Vijayalakshmi, Emmings, Edith , Shetty, Mihir , Chen, Liqiang , Ai, Teng, Meints, Joyce , Lee, Michael K. , Gardner, Melissa, Bazzaro, Martina

Mayo Clinic

Molecular Cancer Research | October 15, 2018 | Volume: 17 | Issue: 2 | Pages: 370-383

10.1158/1541-7786.mcr-18-0670 | PMID 30322860 Get It

Abstract UNC-45A, a highly conserved member of the UCS (UNC45A/CRO1/SHE4P) protein family of cochaperones, plays an important role in regulating cytoskeletal-associated functions in invertebrates and mammalian cells, including cytokinesis, exocytosis, cell motility, and neuronal development. Here, for the first time, UNC-45A is demonstrated to function as a mitotic spindle-associated protein that destabilizes microtubules (MT) activity. Using in vitro biophysical reconstitution and total internal reflection fluorescence microscopy analysis, we reveal that UNC-45A directly binds to taxol-stabilized MTs in the absence of any additional cellular cofactors or other MT-associated proteins and acts as an ATP-independent MT destabilizer. In cells, UNC-45A binds to and destabilizes mitotic spindles, and its depletion causes severe defects in chromosome congression and segregation. UNC-45A is overexpressed in human clinical specimens from chemoresistant ovarian cancer and that UNC-45A–overexpressing cells resist chromosome missegregation and aneuploidy when treated with clinically relevant concentrations of paclitaxel. Lastly, UNC-45A depletion exacerbates paclitaxel-mediated stabilizing effects on mitotic spindles and restores sensitivity to paclitaxel. Implications: These findings reveal novel and significant roles for UNC-45A in regulation of cytoskeletal dynamics, broadening our understanding of the basic mechanisms regulating MT stability and human cancer susceptibility to paclitaxel, one of the most widely used chemotherapy agents for the treatment of human cancers.
Stroke‐related epilepsy
Feyissa, Anteneh M. , Hasan, Tasneem F. , Meschia, James F. , Feyissa, A M , Hasan, T F , Meschia, James F

Mayo Clinic

European Journal of Neurology | October 15, 2018 | Volume: 26 | Issue: 1 | Pages: 18

10.1111/ene.13813 | PMID 30320425 Get It

Stroke is the cause of about 10% of all epilepsy and 55% of newly diagnosed seizures among the elderly. Although recent advances in acute stroke therapy have improved longevity, there has been a consequent rise in the prevalence of stroke‐related epilepsy (STRE). Many clinical studies make a distinction between early (within 7 days of onset of stroke) and late (beyond 7 days of onset of stroke) seizures based on presumed pathophysiological differences. Although early seizures are thought to be the consequence of local metabolic disturbances without altered neuronal networks, late seizures are thought to occur when the brain has acquired a predisposition for seizures. Overall, STRE has a good prognosis, being well controlled by antiepileptic drugs. However, up to 25% of cases become drug resistant. STRE can also result in increased morbidity, longer hospitalization, greater disability at discharge and greater resource utilization. Additional controlled trials are needed to explore the primary and secondary prevention of STRE as well as to provide high‐quality evidence on efficacy and tolerability of antiepileptic drugs to guide treatment of STRE. Robust pre‐clinical and clinical prediction models of STRE are also needed to develop treatments to prevent the transformation of infarcted tissue into an epileptic focus.
“Is there a neurologist on this flight?”
Sirven, Joseph I

Mayo Clinic

Neurology Clinical Practice | October 15, 2018 | Volume: 8 | Issue: 5 | Pages: 445-450

10.1212/cpj.0000000000000505 | PMID 30564499 Get It

Continuous renal replacement therapy during extracorporeal membrane oxygenation: why, when and how?
Ostermann, Marlies , Connor, Michael , Kashani, Kianoush , Ostermann, Marlies

Mayo Clinic

Current Opinion in Critical Care | October 15, 2018 | Volume: 24 | Issue: 6 | Pages: 493-503

10.1097/mcc.0000000000000559 | PMID 30325343 Get It

Purpose of review The use of extracorporeal membrane oxygenation (ECMO) is increasing rapidly. Patients on ECMO have a high risk of developing acute kidney injury (AKI) and needing renal replacement therapy (RRT). The aim of this review is to describe different strategies of combining RRT and ECMO and to outline their advantages and drawbacks. Recent findings Fluid overload is the most common indication for RRT during ECMO, and continuous renal replacement therapy (CRRT) is the most commonly used modality. The optimal timing for initiation of CRRT should be individualized based on degree of fluid overload and severity of AKI-related metabolic derangements. In ECMO patients, CRRT can be provided via an integrated approach (i.e. in-line haemofilter or a fully integrated CRRT device) or a parallel system with separate ECMO and RRT circuits. In-depth knowledge of the resulting intra-circuit pressure changes, risks of air entrapment and haemolysis, and implications for ultrafiltration and solute clearance are essential. There is no evidence that the different methods of combining ECMO and CRRT impact mortality. Summary In patients on ECMO, CRRT can be provided via an integrated approach or independently via parallel systems. An in-depth understanding of the advantages and drawbacks of the different techniques is required.
Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
Abraldeṣ, Juan G. , Trebicka, Jonel , Chalasani, Naga , Shah, Vijay H. , Bosch, Jaime , García–Tsao, Guadalupe , Shah, Vijay H , Bosch, Jaime , Trebicka, Jonel , D’Amico, Gennaro , Rockey, Don C. , Abraldes, Juan G

Mayo Clinic

Hepatology | October 15, 2018 | Volume: 69 | Issue: 3 | Pages: 1287-1299

10.1002/hep.30314 | PMID 30318607 Get It

Portal hypertension (PH) is the main driver of cirrhosis decompensation, the main determinant of death in patients with cirrhosis. PH results initially from increased intrahepatic vascular resistance. Subsequently, increased inflow from splanchnic vasodilation and increased cardiac output lead to a further increase in portal pressure (PP). Reducing PP in cirrhosis results in better outcomes. Removing the cause of cirrhosis might improve PP. However, this is a slow process and patients may continue to be at risk of decompensation. Additionally, for some chronic liver diseases, such as nonalcoholic fatty liver disease (NAFLD), etiological treatments are not yet available. Therefore, there is a need to develop better therapies specifically aimed at reducing PP. For over 35 years, the mainstay of such therapy has been the use of nonselective beta‐blockers (NSBBs) that act by reducing portal venous inflow. Recently, many drugs (mainly targeting intrahepatic mechanisms) have shown promise in preclinical and early clinical studies and may act alone or synergistically with NSBBs in reducing PP in cirrhosis. The objective of this position paper is to propose a novel framework for the design of clinical trials (phase 1, 2, and 3) in patients with cirrhosis and PH and to prioritize targets and pharmacological therapies in this setting. We have focused the discussion on patients with compensated cirrhosis. The paper summarizes discussions held at The American Association for the Study of Liver Diseases (AASLD) Industry Colloquium in January 2018, with the participation of clinical and translational investigators, regulatory professionals, and industry partners.
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Polster, Sean P. , Stadnik, Agnieszka , Akers, Amy , Christoforidis, Gregory A. , Fam, Maged D, Flemming, Kelly D. , Girard, Romuald , Hobson, Nicholas , Koskimäki, Janne , Lane, Karen , Liao, James K. , Lee, Cornelia , Lyne, Séan , McBee, Nichol , Piedad, Kristina , Sorrentino, Matthew J., Thompson, Richard E. , Whitehead, Kevin J. , Zeineddine, Hussein A. , Hanley, Daniel F. , Awad, Issam A. , Girard, Romuald , Hanley, Daniel F , Flemming, Kelly D , Cao, Ying , Hobson, Nicholas, Koenig, James I. , Morrison, Leslie , Shenkar, Robert , Polster, Sean P

Mayo Clinic

Neurosurgery | October 15, 2018 | Volume: 85 | Issue: 6 | Pages: 843-853

10.1093/neuros/nyy539 | PMID 30476251 Get It

Abstract BACKGROUND More than a million Americans harbor a cerebral cavernous angioma (CA), and those who suffer a prior symptomatic hemorrhage have an exceptionally high rebleeding risk. Preclinical studies show that atorvastatin blunts CA lesion development and hemorrhage through inhibiting RhoA kinase (ROCK), suggesting it may confer a therapeutic benefit. OBJECTIVE To evaluate whether atorvastatin produces a difference compared to placebo in lesional iron deposition as assessed by quantitative susceptibility mapping (QSM) on magnetic resonance imaging in CAs that have demonstrated a symptomatic hemorrhage in the prior year. Secondary aims shall assess effects on vascular permeability, ROCK activity in peripheral leukocytes, signal effects on clinical outcomes, adverse events, and prespecified subgroups. METHODS The phase I/IIa placebo-controlled, double-blinded, single-site clinical trial aims to enroll 80 subjects randomized 1-1 to atorvastatin (starting dose 80 mg PO daily) or placebo. Dosing shall continue for 24-mo or until reaching a safety endpoint. EXPECTED OUTCOMES The trial is powered to detect an absolute difference of 20% in the mean percent change in lesional QSM per year (2-tailed, power 0.9, alpha 0.05). A decrease in QSM change would be a signal of potential benefit, and an increase would signal a safety concern with the drug. DISCUSSION With firm mechanistic rationale, rigorous preclinical discoveries, and biomarker validations, the trial shall explore a proof of concept effect of a widely used repurposed drug in stabilizing CAs after a symptomatic hemorrhage. This will be the first clinical trial of a drug aimed at altering rebleeding in CA.
Metabolic Support of the Patient on Continuous Renal Replacement Therapy
Nystrom, Erin M., Nei, Andrea M.

Mayo Clinic

Nutrition in Clinical Practice | October 15, 2018 | Volume: 33 | Issue: 6 | Pages: 754-766

10.1002/ncp.10208 | PMID 30320418 Get It

AbstractContinuous renal replacement therapy (CRRT) is the modality of choice in critically ill patients with hemodynamic instability requiring renal replacement therapy. The goal of this review is to discuss an overview of CRRT types, components, and important considerations for nutrition support provision. Evidence basis for guidelines and our recommendations are reviewed. Nutrition support–related implications include the possibility of calorie gain with citrate‐based anticoagulation, calorie loss with glucose‐free replacement fluids and dialysate, and significant amino acid losses in effluent. We challenge nutrition support clinicians to develop a keen understanding of the specific CRRT modalities that are employed in their intensive care units and to be able to determine how the CRRT prescription may impact a patient's nutrition support prescription.